Join our mailing list for FREE to receive research breakthroughs, news and insights direct to your inbox: hubs.la/Q03pv6Bp0

What if new parents could access more of the support they need in one place? Healthy Babies services are expanding across England, bringing breastfeeding advice, mental health support and early-years guidance to families in every local authority. Explore the story: hubs.la/Q04zvfqh0

AI promises to transform cardiology - but deskilling and "cognitive surrender" are real risks. In this interview, Professor Thomas Lüscher, ESC President, explores why AI should be the co-pilot and the physician the pilot, and what the cardiologist of tomorrow will need to thrive. Read this ahead of our upcoming EMJ Cardiology journal tomorrow: hubs.la/Q04zqy8V0

Every extra 100g of ultra-processed food a day may carry a measurable health cost. The review linked each 100g increment to a 14% higher cardiovascular risk - though the data is observational, not causal. Read more: hubs.la/Q04zqxrT0

What if we could treat myeloma before it becomes clinically active? In the latest Hema Now episode, host Dr Saranya Ravindran speaks with @DrOlaLandgren, Chief of the Division of Myeloma at Sylvester Comprehensive Cancer Center and Professor of Medicine at the University of Miami Miller School of Medicine, about how advances in myeloma research could shape earlier intervention and the future of care. Together, they explore: 🔹Identifying and intervening in myeloma at its earliest stages 🔹The potential of AI in clinical trials and treatment decisions 🔹Tackling resistant disease through investigator-led research 🔹Building greater awareness and understanding of multiple myeloma. Listen now: hubs.la/Q04zpZM80

Could simpler eligibility rules identify more people at risk of inherited breast cancer? Current NHS criteria would have identified just under half of high-penetrance variants, while a streamlined approach increased this to 81%. Read more: hubs.la/Q04zpCCd0

The future of drug development could look very different. In this interview, Lord David Prior, Deputy Chairman and Global Senior Advisor at @Lazard, explores how advances in human cell technologies could reshape clinical research and open new possibilities for medicine. Read more: hubs.la/Q04zjB1p0 #DrugDevelopment #ClinicalResearch #HealthcareInnovation #AnimalTesting Speaker is AI generated.

A new treatment may help transplant patients need fewer anti-rejection drugs. In two high-risk patients, an experimental cell therapy allowed doctors to greatly reduce immunosuppressants without the transplanted organs being rejected for more than five years. The hope: one day, transplant patients may need less lifelong immunosuppression, potentially reducing its side effects. Learn more: hubs.la/Q04z3G4q0

Could cancer risk be identified from birth? Researchers found cancer-predisposing genetic variants in archived newborn blood spots, raising the possibility of identifying some children at risk of early-onset cancer before symptoms develop. Uncover more of the research: hubs.la/Q04z3FP90

The UK's ""silent killer"" is going undetected on a massive scale, new research warns. Data shows 37% of adults have hypertension - and for nearly 60% of them, it has never been diagnosed. Read more: hubs.la/Q04z1gvM0

Could metabolic changes affect lung health before diabetes develops? At #EASD2026, higher glucose levels and lower insulin sensitivity were associated with reduced lung function in adults without diabetes or lung disease. Read more: hubs.la/Q04z0XgQ0 #Diabetes #LungHealth #MetabolicHealth

What could liver function and cholesterol tell us about breast cancer? Researchers identified four liver and lipid markers associated with breast cancer status. The findings are exploratory and do not yet establish these markers as breast cancer risk factors. Explore the research: hubs.la/Q04yY0f90

Could the gut hold new clues to thrombotic risk? Our latest review explores the emerging relationship between the gut microbiome and venous thromboembolism, and its potential implications for diagnosis. Read more: hubs.la/Q04yX-Sm0 #GutMicrobiome #Thrombosis #VTE #CardiovascularHealth Speaker is AI generated.

Cancer therapies are advancing, but what happens when vision is affected? In the latest Onc Now episode, host Dr Catherine Glass speaks with Neel Pasricha, Assistant Professor of Ophthalmology at the University of California, San Francisco, about recognising, monitoring, and managing ocular adverse events associated with cancer therapies. Together, they explore: 🔹 Ocular toxicity linked to antibody–drug conjugates 🔹 Improving screening and adverse event reporting 🔹 Ocular surface electrophysiology and dry eye disease 🔹 Strengthening collaboration across specialties 🎧 Listen now: hubs.la/Q04z03170

What happens when a patient or family feel their concerns aren’t being heard? Martha’s Rule provides a route to request an urgent independent clinical review when a patient’s condition is deteriorating. Now, the initiative is expanding to every A&E in England by 2028. Learn more: hubs.la/Q04yXZSV0

New evidence is taking centre stage on Day 2 of the EADV Congress 2026. From evolving approaches in skin cancer to late-breaking clinical trial findings, today’s programme is spotlighting research with potential relevance for dermatology practice. Join EMJ Dermatology for more Congress insights.: hubs.la/Q04yXB5s0 #EADVCongress #Dermatology #SkinCancer #ClinicalTrials #DermatologyResearch

Are we still missing the families most at risk of premature cardiovascular disease? In the latest EMJ Podcast series, host Catherine Glass speaks with Professor Devaki Nair, Consultant Lipidologist and Clinical Lead for Lipids and Cardiovascular Risk Prevention at the Royal Free Hospital, London, UK, about the developments shaping modern lipidology and cardiovascular prevention. Across a quickfire episode and three deep dives, they explore: 🔹 Why familial hypercholesterolaemia remains underdiagnosed, 🔹 Why Lipoprotein(a) has become one of the hottest topics in preventive cardiology 🔹 When to measure Lipoprotein(a), and how targeted therapies could transform prevention 🔹 How community-based screening can reduce health inequalities in cardiovascular care. 🎧 Listen now: hubs.la/Q04ySGdZ0

Routine blood tests could help identify different risk profiles in Type 2 diabetes. At #EASD2026, immune-based endotyping identified four subgroups with distinct cardiovascular, kidney, and mortality risks. Read more: hubs.la/Q04ySwv30 #Type2Diabetes #Diabetes #PrecisionMedicine

Wildfire smoke may be an important environmental consideration in lung cancer care. Among more than 414,000 patients aged 65 years and older, wildfire-related PM2.5 showed a stronger association with mortality per unit of exposure than particulate pollution from other sources. The observational findings warrant further investigation. Find out more: hubs.la/Q04yNbSw0

Day 1 of the @eadveurope Congress 2026 is underway, bringing new research and clinical developments into focus. From late-breaking data to expert perspectives, EMJ's senior medical writer Jess, gives us a first look at what’s driving conversation in Vienna. Join EMJ Dermatology for more Congress insights: hubs.la/Q04yLd_S0 #EADVCongress #Dermatology #DermatologyResearch #ClinicalTrials

Could a weekly injection ease two major barriers to starting insulin - treatment burden and weight gain? A once-weekly icodec-semaglutide combination cut HbA1c more than daily glargine, with less hypoglycaemia. Explore the findings: hubs.la/Q04yJBLF0